Scholarlink

Background <p>Despite advances in drug-eluting stents (DES), patients with diabetes mellitus (DM) remain at 1.5–2 times higher risk of in-stent restenosis (ISR) than non-diabetics. However, the temporal progression and predictors of severe ISR in this population are not well defined.</p> Methods <p>A retrospective cohort analysis was conducted on 323 diabetic patients who underwent follow-up angiography after everolimus-eluting coronary stenting at a single center between May 2017 to December 2024. The primary outcome was the time to severe ISR (defined as ≥ 70% luminal narrowing). Demographic, clinical, metabolic (including METS-IR), and procedural (Gensini score, lesion characteristics) variables were analyzed. Cox regression identified predictors of accelerated restenosis, and a risk-stratification model was developed and validated internally.</p> Results <p>The median time to severe ISR was 7 months. Independent predictors included elevated D-dimer (HR = 1.001, <i>p</i> = 0.0004), BNP (HR = 1.001, <i>p</i> = 0.0001), METS-IR (HR = 1.378, <i>p</i> = 0.012), Gensini score (HR = 1.004, <i>p</i> = 0.032), and bilateral lesions (HR = 1.242, <i>p</i> = 0.03). Older age was identified as a protective factor, as was higher hemoglobin too. The risk model showed moderate discrimination (AUC = 0.702; sensitivity 68%; specificity 67%) and clinical utility on decision-curve analysis.</p> Conclusion <p>Severe ISR manifests early in diabetics, driven by metabolic dysregulation, thrombotic activity, and procedural complexity. The validated risk-stratification model facilitates personalized surveillance and targeted interventions to mitigate the ISR burden on this vulnerable population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Determinants of time to severe in-stent restenosis in patients with diabetes mellitus after drug-eluting coronary stenting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Fabrice Yves Ndjana Lessomo,
  • Yinhua Luo,
  • Di Fan,
  • Ze Chen,
  • Zhiquan Wang,
  • Zhibing Lu

摘要

Background

Despite advances in drug-eluting stents (DES), patients with diabetes mellitus (DM) remain at 1.5–2 times higher risk of in-stent restenosis (ISR) than non-diabetics. However, the temporal progression and predictors of severe ISR in this population are not well defined.

Methods

A retrospective cohort analysis was conducted on 323 diabetic patients who underwent follow-up angiography after everolimus-eluting coronary stenting at a single center between May 2017 to December 2024. The primary outcome was the time to severe ISR (defined as ≥ 70% luminal narrowing). Demographic, clinical, metabolic (including METS-IR), and procedural (Gensini score, lesion characteristics) variables were analyzed. Cox regression identified predictors of accelerated restenosis, and a risk-stratification model was developed and validated internally.

Results

The median time to severe ISR was 7 months. Independent predictors included elevated D-dimer (HR = 1.001, p = 0.0004), BNP (HR = 1.001, p = 0.0001), METS-IR (HR = 1.378, p = 0.012), Gensini score (HR = 1.004, p = 0.032), and bilateral lesions (HR = 1.242, p = 0.03). Older age was identified as a protective factor, as was higher hemoglobin too. The risk model showed moderate discrimination (AUC = 0.702; sensitivity 68%; specificity 67%) and clinical utility on decision-curve analysis.

Conclusion

Severe ISR manifests early in diabetics, driven by metabolic dysregulation, thrombotic activity, and procedural complexity. The validated risk-stratification model facilitates personalized surveillance and targeted interventions to mitigate the ISR burden on this vulnerable population.